Journal article
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
Abstract
BACKGROUND: Low-molecular-weight heparin has a number of pharmacological and pharmacokinetic advantages over unfractionated heparin that make it potentially suitable, when used in combination with aspirin, for the treatment of unstable coronary artery disease.
METHOD AND RESULTS: Patients with unstable angina or non-Q-wave myocardial infarction (1482) were included in the study, which had two phases. In an open, acute phase (days 1 to 6), …
Authors
Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AGG; van der Meer J; Olaisson E; Undeland S; Ludwig K
Journal
Circulation, Vol. 96, No. 1, pp. 61–68
Publisher
Wolters Kluwer
Publication Date
July 1997
DOI
10.1161/01.cir.96.1.61
ISSN
0009-7322
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAngina, UnstableAnticoagulantsAspirinBlood Coagulation TestsDalteparinDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHeparinHumansInjections, IntravenousInjections, SubcutaneousMaleMiddle AgedMyocardial InfarctionPatient ComplianceProspective StudiesTreatment Outcome